What condition is Raloxifene primarily indicated for?

Raloxifene is primarily indicated for the prevention and treatment of osteoporosis, particularly in postmenopausal women. It belongs to a class of medications known as selective estrogen receptor modulators (SERMs). By mimicking estrogen's beneficial effects on bone density without some of the risks associated with estrogen therapy, Raloxifene helps to maintain or increase bone mineral density, thus reducing the risk of fractures.

In the context of postmenopausal osteoporosis, Raloxifene plays a crucial role as it helps to counteract the increase in bone resorption that occurs due to declining estrogen levels after menopause. This makes it an effective option for women who have a higher risk of osteoporosis-related fractures. While it may have some effects on other conditions, its primary indication is specific to osteoporosis management in the menopausal population.